What is the role of lisocabtagene maraleucel (liso-cel) in chimeric antigen receptor (CAR) T-cell therapy for?

Updated: Dec 17, 2020
  • Author: Sameh Gaballa, MD, MS; Chief Editor: Emmanuel C Besa, MD  more...
  • Print


Liso-cel is an investigational second-generation anti-CD19 CAR T therapy with a 4−1BB costimulatory domain with a fixed ratio of CD4+ to CD8+ T cells. In TRANSCEND NHL 001, a phase I multicenter study in patients with R/R DLBLC that had failed 2 or more lines of therapy, the ORR was 73%, with 53% of patients achieving CR. The toxicity profile was favorable, with a low rate of grade 3 or higher events (cytokine release syndrome, 3%; neurological events, 10%). [21] Based on these results, a biologic license application is currently under priority review by the FDA.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!